Health Care & Life Sciences » Biotechnology | ARCA biopharma Inc.

ARCA biopharma Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
26.00
12.00
19.00
24.00
27.00
22
Gross Income
26.00
12.00
19.00
24.00
27.00
22
SG&A Expense
6,914.00
9,681.00
11,436.00
16,589.00
18,685.00
8,096
EBIT
6,940.00
9,693.00
11,455.00
16,613.00
18,712.00
8,118
Non Operating Income/Expense
4.00
3.00
4.00
-
6.00
8
Pretax Income
6,939.00
9,689.00
11,445.00
16,444.00
18,551.00
7,964
Income Tax
-
-
-
-
61.00
31
Consolidated Net Income
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income After Extraordinaries
6,939.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
Net Income Available to Common
8,965.00
9,689.00
11,445.00
16,444.00
18,490.00
7,933
EPS (Basic)
7.27
3.31
1.82
1.81
1.77
10.31
Basic Shares Outstanding
1,232.80
2,928.70
6,289.30
9,067.40
10,431.40
769.40
EPS (Diluted)
7.27
3.31
1.82
1.81
1.77
10.31
Diluted Shares Outstanding
1,232.80
2,928.70
6,289.30
9,067.40
10,431.40
769.40
EBITDA
6,914.00
9,681.00
11,436.00
16,589.00
18,685.00
8,096
Non-Operating Interest Income
5.00
7.00
14.00
169.00
167.00
162
Preferred Dividends
2,026.00
-
-
-
-
-

About ARCA biopharma

View Profile
Address
11080 CirclePoint Road
Westminster Colorado 80020
United States
Employees -
Website http://www.arcabiopharma.com
Updated 07/08/2019
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications.